HOT-HMV is the first multi-centre, open label, parallel-group, randomised controlled trial to show that home mechanical ventilation (HMV) combined with home oxygen therapy (HOT) significantly reduces the risk of hospital readmission or death in severe COPD patients after an acute COPD exacerbation requiring non-invasive ventilation.
Prof. Nicholas Hart and Dr Patrick Murphy, who led the HOT-HMV trial from St Thomas' Hospital in London
A 51% reduction in the risk of hospital readmission or death in the HOT-HMV arm compared to the HOT arm.
The absolute risk reduction at 12 months was 17%, translating to a need to treat 6 patients to avoid one hospital readmission or death in 12 months.
74% reduction in the risk of hospital readmission in the first 28 days after randomisation with two-thirds fewer events observed in this period.
In addition to the positive effect on time to first readmission or death*, further analysis showed that the exacerbation rate was reduced by 34% in the HOT-HMV arm.
*Median time to first event
High pressure ventilation effectively reduced CO2 levels and therapy was well tolerated as shown by results on quality of life and compliance.
From the European Respiratory Society (ERS) Congress, watch leading investigators from the HOT-HMV trial discussing the study results and their implications in clinical practice.
By listening to the needs of healthcare professionals, patients and the wider COPD care community, we are committed to researching, designing, manufacturing and supporting easy to use, low burden, integrated solutions to help you meet the different needs of individual COPD patients at different stages of the disease continuum.
1. P. Murphy et al., Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. A Randomized Clinical Trial, JAMA. Published online May 21, 2017. doi:10.1001/jama.2017.4451.